X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA SANOFI INDIA AJANTA PHARMA/
SANOFI INDIA
 
P/E (TTM) x 19.9 37.2 53.4% View Chart
P/BV x 4.6 7.0 65.6% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 AJANTA PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
SANOFI INDIA
Dec-17
AJANTA PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,8184,945 36.8%   
Low Rs1,1063,901 28.4%   
Sales per share (Unadj.) Rs239.51,081.8 22.1%  
Earnings per share (Unadj.) Rs52.8141.6 37.3%  
Cash flow per share (Unadj.) Rs59.5185.9 32.0%  
Dividends per share (Unadj.) Rs033.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs230.0868.8 26.5%  
Shares outstanding (eoy) m88.7723.03 385.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.14.1 149.3%   
Avg P/E ratio x27.731.2 88.6%  
P/CF ratio (eoy) x24.623.8 103.3%  
Price / Book Value ratio x6.45.1 124.9%  
Dividend payout %023.3 0.0%   
Avg Mkt Cap Rs m129,782101,862 127.4%   
No. of employees `0006.83.2 209.8%   
Total wages/salary Rs m3,7653,685 102.2%   
Avg. sales/employee Rs Th3,128.47,691.9 40.7%   
Avg. wages/employee Rs Th554.01,137.7 48.7%   
Avg. net profit/employee Rs Th689.71,006.5 68.5%   
INCOME DATA
Net Sales Rs m21,25824,914 85.3%  
Other income Rs m242807 29.9%   
Total revenues Rs m21,49925,721 83.6%   
Gross profit Rs m6,5845,372 122.6%  
Depreciation Rs m5961,022 58.3%   
Interest Rs m411 37.3%   
Profit before tax Rs m6,2265,146 121.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5391,886 81.6%   
Profit after tax Rs m4,6863,260 143.8%  
Gross profit margin %31.021.6 143.6%  
Effective tax rate %24.736.6 67.5%   
Net profit margin %22.013.1 168.5%  
BALANCE SHEET DATA
Current assets Rs m12,23614,432 84.8%   
Current liabilities Rs m3,4616,010 57.6%   
Net working cap to sales %41.333.8 122.1%  
Current ratio x3.52.4 147.3%  
Inventory Days Days6061 98.9%  
Debtors Days Days8428 296.6%  
Net fixed assets Rs m11,1407,991 139.4%   
Share capital Rs m177230 76.8%   
"Free" reserves Rs m20,23719,778 102.3%   
Net worth Rs m20,41420,008 102.0%   
Long term debt Rs m100-   
Total assets Rs m24,48627,770 88.2%  
Interest coverage x1,519.4468.8 324.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.9 96.8%   
Return on assets %19.211.8 162.6%  
Return on equity %23.016.3 140.9%  
Return on capital %30.525.8 118.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,6676,306 185.0%   
Fx outflow Rs m1,6165,257 30.7%   
Net fx Rs m10,0521,049 958.2%   
CASH FLOW
From Operations Rs m2,8544,351 65.6%  
From Investments Rs m-2,604-787 330.9%  
From Financial Activity Rs m-2-1,884 0.1%  
Net Cashflow Rs m2481,680 14.8%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 1.6 14.4 10.8%  
FIIs % 7.6 14.6 52.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.5 161.9%  
Shareholders   20,968 15,184 138.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare AJANTA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 14, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS